IP Library Granted Patent US 7,344,713
Granted Patent B1
US 7,344,713 · App. 08/888,202 · Granted Mar 18, 2008

Decreased fat absorption with an anti-lipase antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,344,713
App. No.
08/888,202
Granted
Mar 18, 2008
Kind
B1
Abstract

A method for the decrease of fat absorption in a mammal, wherein the animal is orally fed an antibody produced against lipase, an enzyme which is required for fat absorption.

Claims (7)

1. A method for decreasing mammalian absorption of fats by the gastrointestinal tract said method comprising inhibiting lipase activity in the mammal, said method comprising the step of: orally administering to the mammal anti-lipase avian antibodies that decrease activity of said lipase relative to a control, wherein said control does not receive said avian antibodies, wherein said inhibiting decreases the breaking down of ingested fats thereby decreasing the absorption of said fats by the gastrointestinal tract.

2. The method of claim 1 , wherein prior to the step of administering to the mammal said avian antibody, said avian antibody is produced in avian eggs.

3. The method of claim 1 , wherein prior to the step of administering said avian antibody, said avian antibody is first freeze dried or spray dried.

4. The method of claim 1 , wherein said avian antibody is fed in a powder form or in liquid form admixed in whole egg or yolk.

5. The method of claim 1 , wherein said avian antibody is fed in a liquid form.

6. A method of reducing weight gain in a mammal by decreasing mammalian absorption of fats in gastrointestinal tract by inhibiting lipase activity in said mammal, said method comprising the step of: orally administering to said mammal an amount of antilipase avian antibodies effective to decrease activity of said lipase relative to control, wherein said control does not receive said avian antibodies, wherein said inhibiting decreases the breaking down of ingested fats thereby decreasing the absorption of said fats by the gastrointestinal tract and reducing weight gain in said mammal.

7. The method of claim 6 wherein said step of orally administering comprises orally administering said antilipase antibody in combination with the mammal's feed.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jul 1, 2024
From: FREEPORT FINANCIAL PARTNERS LLC
To: ANITOX CORP.
Reel/Frame 067887/0077 →
SECURITY INTEREST Recorded Dec 22, 2015
From: ANITOX CORP.
To: FREEPORT FINANCIAL PARTNERS LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 037347/0577 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2009
From: PIMENTEL, JULIO L
To: ANITOX CORPORATION; PIMENTEL, JULIO L
Reel/Frame 022939/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 1998
From: ENERGISER PLC
To: XIMED GROUP PLC
Reel/Frame 009462/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 1998
From: REDUCTOGEN, LTD.
To: ENERGISER PLC
Reel/Frame 009371/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 1998
From: PIMENTEL, JULIO L.
To: REDUCTOGEN LIMITED
Reel/Frame 009200/0500 →